Home › Upcoming votes › Benitec Biopharma Inc.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in Benitec Biopharma Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | ELECTION OF DIRECTORS Director election |
Board | For | 2 nominees; support 97% to 99.5% |
| 2 | RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Auditor |
Board | For | 99.9% support |
| 3 | ADVISORY VOTE ON EXECUTIVE COMPENSATION Say on pay |
Board | For | 78% support |
From Benitec Biopharma Inc.’s Form 8-K, filed December 2, 2025, for the meeting held December 1, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Dr. Jerel Banks | 99.5% | — |
| Elect Director: Megan Boston | 97% | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 99.9% | — |
| 3. Advisory Vote on Executive Compensation | 78% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.